title: Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis.
abstract: The prognosis for myelodysplastic syndrome with bone marrow fibrosis (MDS-F) is worse than the prognosis of MDS without fibrosis. Hematopoietic stem cell transplantation (HSCT) is the only curative therapy; however, the indications and the procedures involved in HSCT remain unclear. We herein describe a 69-year-old Japanese man with MDS-F who received haploidentical HSCT and post-transplantation cyclophosphamide. Although the first HSCT resulted in secondary graft failure, the second HSCT using PTCy led to successful engraftment after early improvement in fibrosis. Since the incidence of graft failure is high in myelofibrosis patients, a secondary HSCT using PTCy may be successful if employed.
authors.affiliation: Department of Hematology, Hokkaido University Graduate School of Medicine, Japan.
authors.forename: Shuichiro
authors.initials: S
authors.lastname: Takahashi
authors.forename: Riko
authors.initials: R
authors.lastname: Tsumanuma
authors.forename: Keiko
authors.initials: K
authors.lastname: Aizawa
authors.forename: Mitsumasa
authors.initials: M
authors.lastname: Osakabe
authors.forename: Kunihiko
authors.initials: K
authors.lastname: Maeda
authors.forename: Ejiro
authors.initials: E
authors.lastname: Omoto
mesh_terms: D000368:Aged; D003520:Cyclophosphamide / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D055728:Primary Myelofibrosis / Q000209:etiology / Q000473:pathology / Q000628:therapy*
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide